STOCK TITAN

Pasithea Therapeutics Corp - KTTA STOCK NEWS

Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.

Pasithea Therapeutics Corp (NASDAQ: KTTA) is a clinical-stage biotechnology company advancing novel therapies for central nervous system disorders and genetic conditions. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress, regulatory milestones, and strategic initiatives.

Our curated collection offers comprehensive tracking of KTTA's developments including clinical trial updates for its lead candidate PAS-004, research collaborations, and advancements in treating conditions like Neurofibromatosis Type 1 and ALS. The content is organized to help stakeholders efficiently monitor the company's progress in neuroscience innovation and drug development.

Key updates cover regulatory filings, partnership announcements, peer-reviewed research publications, and clinical trial results. All content maintains strict editorial standards to ensure accuracy and relevance for both professional investors and those new to biotech equities.

Bookmark this page for centralized access to verified information about Pasithea's therapeutic pipeline, including its work on MEK inhibitors and translational medicine approaches. Check back regularly for essential updates that could impact long-term research trajectories and market positioning.

Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotech company, will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company is developing PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other cancer indications.

Key points:

  • Presentation available online from 7:00 a.m. ET on September 9th, 2024
  • Management to conduct 1x1 meetings from September 9-11, 2024
  • Conference held at the Lotte New York Palace Hotel
  • Registration available at https://hcwevents.com/annualconference/
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
-
Rhea-AI Summary

Pasithea Therapeutics has completed enrollment and initial dosing for the second cohort in its Phase 1 clinical trial of PAS-004, a macrocyclic MEK inhibitor aimed to treat neurofibromatosis type 1 (NF1) and other conditions. The Safety Review Committee (SRC) recommended escalating to the next dose level (4mg) after a positive safety review of the first dose cohort (2mg), which showed no dose-limiting toxicities or clinically relevant adverse events. The trial, involving patients with advanced solid tumors driven by MAPK pathway mutations, aims to assess the safety, tolerability, and pharmacokinetics (PK) of PAS-004. Initial safety and PK data are expected by Q3 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary

Pasithea Therapeutics announced new preclinical data for PAS-004, revealing its strong inhibition of NRAS mutant cancer cell lines and superior activity in xenograft studies. PAS-004 demonstrated greater efficacy than selumetinib and binimetinib, comparable efficacy to trametinib without plateauing, and achieved over 50% maximal growth inhibition in more cell lines. The data will be presented at the ASCO Annual Meeting on June 1, 2024. PAS-004, a macrocyclic MEK inhibitor, is in clinical trials for neurofibromatosis type 1 (NF1) and other cancers, offering potential advantages in pharmacokinetics, pharmacodynamics, and tolerability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
conferences clinical trial
Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the acceptance of an abstract for poster presentation at the 2024 ASCO Annual Meeting for their drug PAS-004, a macrocyclic MEK inhibitor targeting neurofibromatosis type 1 (NF1) and other indications. The drug is the first of its kind in human clinical trials, offering extended half-life for improved efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. announces the completion of initial dosing for the first cohort in a Phase 1 trial evaluating PAS-004 in RAS, NF1, and RAF mutated cancers. Safety, tolerability, and biomarker data expected in 2H 2024. PAS-004 is a next-generation MEK inhibitor for neurofibromatosis type 1 (NF1) and other indications, showing potential as a best-in-class inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the activation of four U.S. clinical trial sites for Phase 1 trial of PAS-004, a next-generation MEK inhibitor for treating NF1 and other cancer indications. The company plans to open three more sites in Eastern Europe. Preliminary interim data is expected in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.95%
Tags
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announces the invention of a crystalline form of PAS-004, extending patent protection to at least 2045. The company is focused on developing innovative treatments for CNS disorders, with a strong emphasis on expanding its patent portfolio and increasing the value of PAS-004 through additional CMC development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the FDA clearance to evaluate PAS-004, a macrocyclic MEK inhibitor, in patients with MAPK pathway driven advanced solid tumors. The phase 1 dose escalation study is expected to begin in Q1 2024, with an initial readout anticipated as early as Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns stockholder meeting to provide additional time for voting on charter amendment proposals. The reconvened meeting will take place on December 29, 2023, with the original record date remaining the same. Stockholders are encouraged to vote promptly, and proxies previously submitted will be voted at the adjourned meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
none
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) Holds Annual Meeting and Receives Overwhelming Support for Approved Proposals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.58%
Tags
none
Pasithea Therapeutics Corp

Nasdaq:KTTA

KTTA Rankings

KTTA Stock Data

3.73M
2.46M
19.08%
6.09%
0.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH